Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3051
Aquestive Therapeutics
AQST
$532M
| $417K | ﹤0.01% |
462,737
-438,063
| -49% | -$411K |
|
|
CYPH
3052
Cypherpunk Technologies Inc
CYPH
$70M
| $417K | ﹤0.01% |
92,570
+53,440
| +137% | +$357K |
|
3053
Dare Bioscience
DARE
$13.7M
| $416K | ﹤0.01% |
41,724
-12,443
| -23% | -$139K |
|
3054
Telephone and Data Systems
TDS
$4.04B
| $415K | ﹤0.01% |
+39,584
| New | +$490K |
|
3055
ProShares Short Bitcoin Strategy ETF
BITI
$121M
| $414K | ﹤0.01% |
+2,080
| New | +$407K |
|
|
OCFT
3056
DELISTED
OneConnect Financial Technology
OCFT
| $414K | ﹤0.01% |
78,060
-2,310
| -3% | -$15.9K |
|
3057
Dimensional US Core Equity 2 ETF
DFAC
$49.9B
| $413K | ﹤0.01% |
17,000
-40,800
| -71% | -$992K |
|
3058
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
$7.62B
| $413K | ﹤0.01% |
+10,100
| New | +$413K |
|
3059
Silicom
SILC
$285M
| $413K | ﹤0.01% |
9,803
+4,003
| +69% | +$165K |
|
|
EEX
3060
DELISTED
Emerald Holding
EEX
| $411K | ﹤0.01% |
116,057
-19,580
| -14% | -$70.2K |
|
3061
Dorchester Minerals
DMLP
$1.37B
| $410K | ﹤0.01% |
13,700
+1,000
| +8% | +$28.8K |
|
|
HI
3062
DELISTED
Hillenbrand
HI
| $410K | ﹤0.01% |
9,600
-34,600
| -78% | -$1.53M |
|
3063
VirnetX Holding Corp
VHC
$61.1M
| $408K | ﹤0.01% |
15,697
-15,273
| -49% | -$378K |
|
3064
ARK Autonomous Technology & Robotics ETF
ARKQ
$2.1B
| $406K | ﹤0.01% |
9,900
-14,700
| -60% | -$648K |
|
3065
First Trust Dow Jones Internet Index Fund ETF
FDN
$5.38B
| $406K | ﹤0.01% |
3,300
-1,100
| -25% | -$140K |
|
3066
AYTU BioPharma
AYTU
$25.5M
| $405K | ﹤0.01% |
107,039
+19,663
| +23% | +$74K |
|
3067
Vanguard FTSE Europe ETF
VGK
$31B
| $405K | ﹤0.01% |
+7,300
| New | +$385K |
|
3068
Bank7 Corp
BSVN
$498M
| $404K | ﹤0.01% |
15,800
+4,420
| +39% | +$112K |
|
3069
Cue Biopharma
CUE
$143M
| $404K | ﹤0.01% |
4,723
-9,482
| -67% | -$867K |
|
3070
JPMorgan Diversified Return International Equity ETF
JPIN
$375M
| $404K | ﹤0.01% |
+8,200
| New | +$386K |
|
3071
KALA BIO
KALA
$17.8M
| $404K | ﹤0.01% |
212
+37
| +21% | +$14.6K |
|
3072
Pulmatrix
PULM
$5.51M
| $404K | ﹤0.01% |
104,120
-8,100
| -7% | -$29.3K |
|
3073
Pliant Therapeutics
PLRX
$67.5M
| $402K | ﹤0.01% |
20,800
-73,500
| -78% | -$1.54M |
|
3074
Hartford Multifactor Developed Markets ex-US ETF
RODM
$1.66B
| $402K | ﹤0.01% |
+16,200
| New | +$387K |
|
|
LND
3075
BrasilAgro
LND
$357M
| $401K | ﹤0.01% |
70,500
-39,700
| -36% | -$220K |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.